These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

698 related articles for article (PubMed ID: 31591590)

  • 1. Developing neoantigen-targeted T cell-based treatments for solid tumors.
    Yamamoto TN; Kishton RJ; Restifo NP
    Nat Med; 2019 Oct; 25(10):1488-1499. PubMed ID: 31591590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized T cell-mediated cancer immunotherapy: progress and challenges.
    Bethune MT; Joglekar AV
    Curr Opin Biotechnol; 2017 Dec; 48():142-152. PubMed ID: 28494274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in personalized neoantigen vaccines for cancer immunotherapy.
    Sun C; Xu S
    Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An effective mouse model for adoptive cancer immunotherapy targeting neoantigens.
    Hanada KI; Yu Z; Chappell GR; Park AS; Restifo NP
    JCI Insight; 2019 May; 4(10):. PubMed ID: 31092734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
    Roerden M; Nelde A; Walz JS
    Front Immunol; 2019; 10():3004. PubMed ID: 31921218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential.
    Poorebrahim M; Mohammadkhani N; Mahmoudi R; Gholizadeh M; Fakhr E; Cid-Arregui A
    Cancer Gene Ther; 2021 Jun; 28(6):581-589. PubMed ID: 33654227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterizing neoantigens for personalized cancer immunotherapy.
    Capietto AH; Jhunjhunwala S; Delamarre L
    Curr Opin Immunol; 2017 Jun; 46():58-65. PubMed ID: 28478383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants for Neoantigen Identification.
    Garcia-Garijo A; Fajardo CA; Gros A
    Front Immunol; 2019; 10():1392. PubMed ID: 31293573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation-Derived Neoantigens for Cancer Immunotherapy.
    Castle JC; Uduman M; Pabla S; Stein RB; Buell JS
    Front Immunol; 2019; 10():1856. PubMed ID: 31440245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.
    Yossef R; Tran E; Deniger DC; Gros A; Pasetto A; Parkhurst MR; Gartner JJ; Prickett TD; Cafri G; Robbins PF; Rosenberg SA
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery.
    de Sousa E; Lérias JR; Beltran A; Paraschoudi G; Condeço C; Kamiki J; António PA; Figueiredo N; Carvalho C; Castillo-Martin M; Wang Z; Ligeiro D; Rao M; Maeurer M
    Front Immunol; 2021; 12():592031. PubMed ID: 34335558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoantigens in cancer immunotherapy.
    Schumacher TN; Schreiber RD
    Science; 2015 Apr; 348(6230):69-74. PubMed ID: 25838375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MHC class II restricted neoantigen: A promising target in tumor immunotherapy.
    Sun Z; Chen F; Meng F; Wei J; Liu B
    Cancer Lett; 2017 Apr; 392():17-25. PubMed ID: 28104443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personal Neoantigen Cancer Vaccines: A Road Not Fully Paved.
    Fritsch EF; Burkhardt UE; Hacohen N; Wu CJ
    Cancer Immunol Res; 2020 Dec; 8(12):1465-1469. PubMed ID: 33262163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4.
    van den Bulk J; Verdegaal EME; Ruano D; Ijsselsteijn ME; Visser M; van der Breggen R; Duhen T; van der Ploeg M; de Vries NL; Oosting J; Peeters KCMJ; Weinberg AD; Farina-Sarasqueta A; van der Burg SH; de Miranda NFCC
    Genome Med; 2019 Dec; 11(1):87. PubMed ID: 31888734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor neoantigens: building a framework for personalized cancer immunotherapy.
    Gubin MM; Artyomov MN; Mardis ER; Schreiber RD
    J Clin Invest; 2015 Sep; 125(9):3413-21. PubMed ID: 26258412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NEPdb: A Database of T-Cell Experimentally-Validated Neoantigens and Pan-Cancer Predicted Neoepitopes for Cancer Immunotherapy.
    Xia J; Bai P; Fan W; Li Q; Li Y; Wang D; Yin L; Zhou Y
    Front Immunol; 2021; 12():644637. PubMed ID: 33927717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
    Aldous AR; Dong JZ
    Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of neoantigens for individualized therapeutic cancer vaccines.
    Lang F; Schrörs B; Löwer M; Türeci Ö; Sahin U
    Nat Rev Drug Discov; 2022 Apr; 21(4):261-282. PubMed ID: 35105974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.